A Randomised Phase II Trial of Weekly Docetaxel (Taxotere) Chemoradiotherapy +/- Cetuximab (Erbitux) for Localised Resectable Cancer of the Oesophagus

Phase 2

• Conditions: ocalised resectable cancer of the oesophagus; Localised resectable cancer of the oesophagus; Cancer - Oesophageal (gullet)

• Registration Number: ACTRN12608000382370
• Lead Sponsor: Australasian Gastro-Intestinal Trials Group (AGITG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-08-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Adenocarcinoma of the oesophagus or oesophago-gastric junction, suitable for definitive surgical resection.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Exclusion Criteria

Distant visceral or nodal metastases.
Previous chemotherapy or radiotherapy for oesophageal cancer.
Carcinoma of the cervical oesophagus, or tumour predominantly in the stomach.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pathological complete response rate determined from surgical specimens in resectable patients[Surgery will be performed 4-8 weeks following completion of chemoradiotherapy in resectable patients]